Do you want to read an article? Please log in or register.
Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients
Macular Diseases
COMMENTED
Related content
Macular Diseases
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab
JAMA Ophthalmol.
Parikh R, Avery RL, Saroj N, Thompson D, Freund KB
doi: 10.1001/jamaophthalmol.2019.1947.
Glaucoma and Ocular PressureMacular DiseasesOcular Oncology
Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
Invest Ophthalmol Vis Sci.
Wen JC, Reina-Torres E, Sherwood JM, Challa P, Liu KC, Li G, Chang JY, Cousins SW, Schuman SG, Mettu PS, Stamer WD, Overby DR, Allingham RR
doi: 10.1167/iovs.16-20786.
Macular Diseases
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
JAMA Ophthalmol.
Ramakrishnan MS, Yu Y, VanderBeek BL
doi: 10.1001/jamaophthalmol.2019.4577.
Macular Diseases
Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration
Acta Ophthalmol.
Jelin E, Wisløff T, Moe MC, Heiberg T
doi: 10.1111/aos.13847.
Macular Diseases
Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
JAMA Ophthalmol.
Subhi Y, Krogh Nielsen M, Molbech CR, Krüger Falk M, Singh A, Hviid TVF, Nissen MH, Sørensen TL
doi: 10.1001/jamaophthalmol.
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
COMMENTED
Macular Diseases
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM
doi: 10.1001/jamaophthalmol.2020.5053
Macular Diseases
Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration
Acta Ophthalmol.
Mitsch C, Pemp B, Pollreisz A, Gleiss A, Karst S, Scholda C, Sacu S, Schmidt-Erfurth U
doi: 10.1111/aos.14276.Visit the original publication at ncbi.nlm.nih.gov
Macular Diseases
AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study
Retina.
Blanco-Garavito R, Jung C, Uzzan J, Quaranta-ElMaftouhi M, Coscas F, Sahel J, Korobelnik JF, Béchet S, Querques G, Souied EH
doi: 10.1097/IAE.